HSDT (Solana Company Class A Common Stock (DE))
Insider Trading Activity
Every open-market purchase and sale reported by HSDT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-04 | Choon Wee Chee | CEO and President | A | — | — |
| 2026-07-13 | Summer Wisdom Holdings Ltd | 10%+ Owner | J | — | — |
| 2026-06-04 | Cosmo Yi Jiang | Director | A | — | — |
| 2026-06-04 | Cosmo Yi Jiang | Director | MIXED | — | — |
| 2026-05-26 | Sergio Mello | Director | A | — | — |
| 2026-05-26 | Blane Walter | Director | A | — | — |
| 2026-05-26 | EDWARD M STRAW | Director | A | — | — |
| 2026-05-26 | Blane Walter | Director | A | — | — |
| 2026-05-26 | EDWARD M STRAW | Director | A | — | — |
| 2026-05-26 | Michel Kai Tai Lee | Director | A | — | — |
| 2026-05-22 | Fusion Summer Ltd | 10%+ Owner | J | — | — |
| 2026-05-13 | Choon Wee Chee | Executive Chairman | M | — | — |
| 2026-04-02 | Blane Walter | Director | A | — | — |
| 2026-04-02 | PAUL BUCKMAN | Director | A | — | — |
| 2026-04-02 | Sherrie L Perkins | Director | A | — | — |
| 2026-04-02 | EDWARD M STRAW | Director | A | — | — |
| 2025-07-03 | Sherrie L Perkins | Director | A | — | — |
| 2025-07-03 | PAUL BUCKMAN | Director | A | — | — |
| 2025-07-03 | Pelt Antonella R. Favit-Van | Chief Medical Officer | A | — | — |
| 2025-07-03 | DANE ANDREEFF | President and CEO | A | — | — |
| 2025-07-03 | JEFFREY S MATHIESEN | CFO and Treasurer | A | — | — |
| 2025-07-03 | EDWARD M STRAW | Director | A | — | — |
| 2025-07-03 | Blane Walter | Director | A | — | — |
| 2025-01-08 | EDWARD M STRAW | Director | A | — | — |
| 2025-01-08 | JEFFREY S MATHIESEN | CFO and Treasurer | A | — | — |
| 2025-01-08 | PAUL BUCKMAN | Director | A | — | — |
| 2025-01-08 | Pelt Antonella R. Favit-Van | Chief Medical Officer | A | — | — |
| 2025-01-08 | DANE ANDREEFF | President and CEO | A | — | — |
| 2025-01-08 | Blane Walter | Director | A | — | — |
| 2025-01-08 | Sherrie L Perkins | Director | A | — | — |
| 2024-07-05 | Blane Walter | Director | A | — | — |
| 2024-07-05 | EDWARD M STRAW | Director | A | — | — |
| 2024-07-05 | Sherrie L Perkins | Director | A | — | — |
| 2024-07-05 | Pelt Antonella R. Favit-Van | Chief Medical Officer | A | — | — |
| 2024-07-05 | PAUL BUCKMAN | Director | A | — | — |
| 2024-07-05 | DANE ANDREEFF | President and CEO | A | — | — |
| 2024-07-05 | JEFFREY S MATHIESEN | CFO and Treasurer | A | — | — |
| 2024-02-15 | DANE ANDREEFF | President and CEO | Buy | — | — |
| 2023-12-15 | DANE ANDREEFF | President and CEO | Buy | — | — |
| 2023-12-04 | DANE ANDREEFF | President and CEO | Buy | — | — |
| 2023-08-30 | DANE ANDREEFF | President and CEO | Buy | — | — |
| 2023-05-26 | Blane Walter | Director | A | — | — |
| 2023-05-26 | Sherrie L Perkins | Director | A | — | — |
| 2023-05-26 | EDWARD M STRAW | Director | A | — | — |
| 2023-05-26 | PAUL BUCKMAN | Director | A | — | — |
| 2023-02-16 | JEFFREY S MATHIESEN | CFO and Treasurer | A | — | — |
| 2023-02-16 | Pelt Antonella R. Favit-Van | Chief Medical Officer | A | — | — |
| 2023-02-16 | DANE ANDREEFF | President and CEO | A | — | — |
| 2022-12-19 | DANE ANDREEFF | President and CEO | Buy | — | — |
| 2022-11-25 | DANE ANDREEFF | President and CEO | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | CEO and President | 6,486,243 | — |
| — | 10%+ Owner | 5,377,125 | — |
| — | 10%+ Owner | 5,377,125 | — |
| — | Director | 1,004,430 | — |
| — | Director | 92,220 | — |
| — | Director | 92,004 | — |
| — | Director | 8,542 | — |
| — | Director | 8,542 | — |
| — | Director | 6,360 | — |
| — | Director | 6,360 | — |
| — | President and CEO | 3 | — |
| — | Director | 1 | — |
| — | President and CEO | 1 | — |
| — | Chief Medical Officer | 1 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the HSDT quote page; the site-wide leaderboard is on the insider transactions hub.